NDAORALCAPSULEPriority Review
Approved
Jun 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
7
Data completeness
5/8 — Partial
Priority Review
IBTROZI (taletrectinib) by Nuvation is ros1, including ros1 resistance mutations. First approved in 2025.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IBTROZI (taletrectinib) is an oral small-molecule ROS1 tyrosine kinase inhibitor approved for ROS1-positive non-small cell lung cancer, including tumors with ROS1 resistance mutations. The drug works by inhibiting ROS1 fusion proteins and their downstream signaling pathways, with additional activity against tropomyosin receptor kinases (TRK). Taletrectinib demonstrated tumor growth inhibition in preclinical models, including intracranial NSCLC xenografts.
Growth6.7 years to LOE
Early commercial lifecycle with no competitive pressure presents opportunity for market definition and team build-out in a newly approved indication.
Mechanism of Action
ROS1, including ROS1 resistance mutations. Taletrectinib also showed inhibitory effects on tropomyosin receptor kinases (TRKs) TRKA, TRKB, and TRKC. Fusion proteins that include ROS1 domains can drive tumorigenic potential through hyperactivation of downstream signaling pathways leading to…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib
Started Aug 2026
56 enrolled
Healthy Adult Participants
Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression
Started Oct 2025
50 enrolled
Non-small Lung Cancer
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Started Aug 2025
180 enrolled
Non-small Cell Lung Cancer (NSCLC)
Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases
Started Jun 2025
100 enrolled
Non-Small Cell Lung Cancer
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Started Nov 2024
194 enrolled
Non Small Cell Lung Cancer
Worked on IBTROZI at Nuvation? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.